1.
OMS. Stratégie de l’OMS pour la médecine traditionnelle pour 2002- 2005. Genève : Organisation mondiale de la Santé, 2002 : 1–78.
2.
Harris P, Rees R. The prevalence of complementary and alternative medicine use among the general population : a systematic review of the literature. Compl Ther Med 2000; 8 : 88–96.
3.
Eisenberg DM, Kessler RC, Van Rompay MI, et al.Perceptions about complementary therapies relative to conventional therapies among adults who use both : results from a national survey. Ann Intern Med 2001; 135 : 344–51.
4.
Rossouw JE, Anderson GL, Prentice RL, et al.Risks and benefits of estrogen plus progestin in healthy postmenopausal women : principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288 : 321–33.
5.
Ross JA, Kasum CM. Dietary flavonoids : bioavailability, metabolic effects, and safety. Annu Rev Nutr 2002; 22 : 19–34.
6.
Lock M, Kaufert P, Gilbert P. Cultural construction of the menopausal syndrome : the Japanese case. Maturitas 1988; 10 : 317–32.
7.
Kronenberg F, Fugh-Berman A. Complementary and alternative medicine for menopausal symptoms : a review of randomized, controlled trials. Ann Intern Med 2002; 137 : 805–13.
8.
Setchell KD, Brown NM, Zimmer-Nechemias L, et al.Evidence for lack of absorption of soy isoflavone glycosides in humans, supporting the crucial role of intestinal metabolism for bioavailability. Am J Clin Nutr 2002; 76 : 447–53.
9.
Adlercreutz H. Phyto-oestrogens and cancer. Lancet Oncol 2002; 3 : 364–73.
10.
Anthony MS. Soy and cardiovascular disease : cholesterol lowering and beyond. J Nutr 2000; 130 : 662S–3S.
11.
Clarkson TB, Anthony MS, Morgan TM. Inhibition of postmenopausal atherosclerosis progression : a comparison of the effects of conjugated equine estrogens and soy phytoestrogens. J Clin Endocrinol Metab 2001; 86 : 41–7.
12.
Anderson JW, Johnstone BM, Cook-Newell ME. Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med 1995; 333 : 276–82.
13.
Warren MP, Shortle B, Dominguez JE. Use of alternative therapies in menopause. Best Pract Res Clin Obstet Gynaecol 2002; 16 : 411–48.
14.
Lucas EA, Wild RD, Hammond LJ, et al.Flaxseed improves lipid profile without altering biomarkers of bone metabolism in postmenopausal women. J Clin Endocrinol Metab 2002; 87 : 1527–32.
15.
Lemay A, Dodin S, Kadri N, Jacques H, Forest JC. Flaxseed dietary supplement versus hormone replacement therapy in hypercholesterolemic menopausal women. Obstet Gynecol 2002; 100 : 495–504.
16.
Uesugi T, Fukui Y, Yamori Y. Beneficial effects of soybean isoflavone supplementation on bone metabolism and serum lipids in postmenopausal japanese women : a fourweek study. J Am Coll Nutr 2002; 21 : 97–102.
17.
Wangen KE, Duncan AM, Merz-Demlow BE, et al.Effects of soy isoflavones on markers of bone turnover in premenopausal and postmenopausal women. J Clin Endocrinol Metab 2000; 85 : 3043–8.
18.
Horn-Ross PL, John EM, Lee M, et al.Phytoestrogen consumption and breast cancer risk in a multiethnic population : the Bay Area Breast Cancer Study. Am J Epidemiol 2001; 154 : 434–41.
19.
Wu AH, Wan P, Hankin J, Tseng CC, Yu MC, Pike MC. Adolescent and adult soy intake and risk of breast cancer in Asian-Americans. Carcinogenesis 2002; 23 : 1491–6.
20.
Shu XO, Jin F, Dai Q, et al.Soyfood intake during adolescence and subsequent risk of breast cancer among Chinese women. Cancer Epidemiol Biomarkers Prev 2001; 10 : 483–8.
21.
McMichael-Phillips DF, Harding C, Morton M, et al.Effects of soy-protein supplementation on epithelial proliferation in the histologically normal human breast. Am J Clin Nutr 1998; 68 : 1431S–1435S.
22.
Hargreaves DF, Potten CS, Harding C, et al.Two-week dietary soy supplementation has an estrogenic effect on normal premenopausal breast. J Clin Endocrinol Metab 1999; 84 : 4017–24.
23.
Maskarinec G, Williams AE, Carlin L. Mammographic densities in a one-year isoflavone intervention. Eur J Cancer Prev 2003; 12 : 165–9.
24.
Baber RJ, Templeman C, Morton T, Kelly GE, West L. Randomized placebocontrolled trial of an isoflavone supplement and menopausal symptoms in women. Climacteric 1999; 2 : 85–92.
25.
Dalais FS, Rice GE, Wahlqvist ML, et al. Effects of dietary phytoestrogens in postmenopausal women. Climacteric 1998; 1 : 124–9.
26.
Upmalis DH, Lobo R, Bradley L, Warren M, Cone FL, Lamia CA. Vasomotor symptom relief by soy isoflavone extract tablets in postmenopausal women a multicenter, double-blind, randomized, placebo-controlled study. Menopause 2000; 7 : 236–42.
27.
St Germain A, Peterson CT, Robinson JG, Alekel DL. Isoflavone-rich or isoflavone-poor soy protein does not reduce menopausal symptoms during 24 weeks of treatment. Menopause 2001; 8 : 17–26.
28.
Knight DC, Howes JB, Eden JA. The effect of Promensil, an isoflavone extract, on menopausal symptoms. Climacteric 1999; 2 : 79–84.
29.
Quella SK, Loprinzi CL, Barton DL, et al.Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors. A North Central cancer treatment group trial. J Clin Oncol 2000; 18 : 1068–74.
30.
Han KK, Soares JM, Jr., Haidar MA, de Lima GR, Baracat EC. Benefits of soy isoflavone therapeutic regimen on menopausal symptoms. Obstet Gynecol 2002; 99 : 389–94.
31.
Murkies AL, Lombard C, Strauss BJ, Wilcox G, Burger HG, Morton MS. Dietary flour supplementation decreases post-menopausal hot flushes effect of soy and wheat. Maturitas 1995; 21 : 189–95.
32.
Knight DC, Howes JB, Eden JA, Howes LG. Effects on menopausal symptoms and acceptability of isoflavone-containing soy powder dietary supplementation. Climacteric 2001; 4 : 13–8.
33.
Scambia G, Mango D, Signorile PG, et al. Clinical effects of a standardized soy extract in postmenopausal women a pilot study. Menopause 2000; 7 : 105–11.
34.
Van Patten CL, Olivotto IA, Chambers GK, et al.Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer a randomized, controlled clinical trial. J Clin Oncol 2002; 20 : 1449–55.
35.
Kotsopoulos D, Dalais FS, Liang YL, McGrath BP, Teede HJ. The effects of soy protein containing phytoestrogens on menopausal symptoms in postmenopausal women. Climacteric 2000; 3 : 161–7.
36.
Washburn S, Burke GL, Morgan T, Anthony M. Effect of soy protein supplementation on serum lipoproteins, blood pressure, and menopausal symptoms in perimenopausal women. Menopause 1999; 6 : 7–13.
37.
Albertazzi P, Pansini F, Bonaccorsi G, Zanotti L, Forini E, De Aloysio D. The effect of dietary soy supplementation on hot flushes. Obstet Gynecol 1998; 91 : 6–11.
38.
Brzezinski A, Adlercreutz H, Shaoul R, Rosler A, Shmueli A, Tanos Vea. Short-term effect of phytoestrogen-rich diet on postmenopausal women. Menopause 1997; 4 : 89–94.
39.
Baird DD, Umbach DM, Lansdell L, et al. Dietary intervention study to assess estrogenicity of dietary soy among postmenopausal women. J Clin Endocrinol Metab 1995; 80 : 1685–90.
40.
Chiechi LM, Secreto G, D’Amore M, et al. Efficacy of a soy rich diet in preventing postmenopausal osteoporosis the Menfis randomized trial. Maturitas 2002; 42 : 295–300.
41.
Clifton-Bligh PB, Baber RJ, Fulcher GR, Nery ML, Moreton T. The effect of isoflavones extracted from red clover (Rimostil) on lipid and bone metabolism. Menopause 2001; 8 : 259–65.
42.
Alekel DL, Germain AS, Peterson CT, Hanson KB, Stewart JW, Toda T. Isoflavone-rich soy protein isolate attenuates bone loss in the lumbar spine of perimenopausal women. Am J Clin Nutr 2000; 72 : 844–52.
43.
Potter SM, Baum JA, Teng H, Stillman RJ, Shay NF, Erdman JW Jr. Soy protein and isoflavones their effects on blood lipids and bone density in postmenopausal women. Am J Clin Nutr 1998; 68: 1375S–9S.
44.
Dai Q, Franke AA, Jin F, et al. Urinary excretion of phytoestrogens and risk of breast cancer among Chinese women in Shanghai. Cancer Epidemiol Biomarkers Prev 2002; 11 : 815–21.
45.
Pietinen P, Stumpf K, Mannisto S, Kataja V, Uusitupa M, Adlercreutz H. Serum enterolactone and risk of breast cancer a case-control study in eastern Finland. Cancer Epidemiol Biomarkers Prev 2001; 10 : 339–44.
46.
McCann SE, Moysich KB, Freudenheim JL, Ambrosone CB, Shields PG. The risk of breast cancer associated with dietary lignans differs by CYP17 genotype in women. J Nutr 2002; 132 : 3036–41.
47.
Zheng W, Dai Q, Custer LJ, et al. Urinary excretion of isoflavonoids and the risk of breast cancer. Cancer Epidemiol Biomarkers Prev 1999; 8 : 35–40.
48.
den Tonkelaar I, Keinan-Boker L, Veer PV, et al. Urinary phytoestrogens and postmenopausal breast cancer risk. Cancer Epidemiol Biomarkers Prev 2001; 10 : 223–8.
49.
Murkies A, Dalais FS, Briganti EM, et al. Phytoestrogens and breast cancer in postmenopausal women a case control study. Menopause 2000; 7 : 289–96.
50.
Torres-Sanchez L, Lopez-Carrillo L, Lopez-Cervantes M, Rueda-Neria C, Wolff MS. Food sources of phytoestrogens and breast cancer risk in Mexican women. Nutr Cancer 2000; 37 : 134–9.
51.
Dai Q, Shu XO, Jin F, et al. Population-based casecontrol study of soyfood intake and breast cancer risk in Shanghai. Br J Cancer 2001; 85 : 372–8.
52.
Wu AH, Ziegler RG, Horn-Ross PL, et al. Tofu and risk of breast cancer in Asian-Americans. Cancer Epidemiol Biomarkers Prev 1996; 5 : 901–6.
53.
Ingram D, Sanders K, Kolybaba M, Lopez D. Case-control study of phyto-oestrogens and breast cancer. Lancet 1997; 350 : 990–4.
54.
Witte JS, Ursin G, Siemiatycki J, Thompson WD, Paganini-Hill A, Haile RW. Diet and premenopausal bilateral breast cancer a case-control study. Breast Cancer Res Treat 1997; 42 : 243–51.